Suppr超能文献

[一种诱导人抗肿瘤效应性CD4+和CD8+ T细胞的有效方法:其在肿瘤免疫治疗中的应用]

[An efficient methods for the induction of human antitumor effector CD4+ and CD8+ T cells: their application to tumor immunotherapy].

作者信息

Nishimura T, Kuge S, Watanabe K, Lee U, Yahata T, Habu S

机构信息

Department of Immunology, Tokai University School of Medicine, Isehara, Japan.

出版信息

Hum Cell. 1994 Sep;7(3):131-7.

PMID:7873496
Abstract

It is an important issues to investigate an efficient methods to induce antitumor effector T cells from peripheral blood lymphocytes of tumor patients for the development of a novel tumor immunotherapy. We established a large scale culture system of human CD4+ helper/killer T cells which have both helper and killer functions. Targeting of CD4+ helper/killer T cells to tumor using anti-CD3 x anti-c-erbB-2 mAb caused the lysis of tumor and triggering of IL-2 production. It was also demonstrated that culture of human CD4+ T cells with staphylococcal enterotoxin A (SEA) or IL-12 caused a selective induction of Th1 type of CD4+ helper/killer T cells. IL-12 also revealed a novel effect on CD8+CTL functions. Culture of CD8+ T cells with IL-12 resulted in the augmentation of IFN-gamma production and cytotoxicity. Moreover, culture of tumor-infiltrating lymphocytes with IL-12 caused a marked enhancement of CD8+CTL against autologous tumor cells. These findings suggest that IL-12 will become a useful cytokine for the tumor immunotherapy. In this paper, we will discuss the key role of CD4+ T cells for the induction of antitumor immunity in tumor-bearing host.

摘要

研究从肿瘤患者外周血淋巴细胞诱导抗肿瘤效应T细胞的有效方法对于新型肿瘤免疫疗法的发展是一个重要问题。我们建立了一种大规模培养具有辅助和杀伤功能的人CD4+辅助/杀伤T细胞的系统。使用抗CD3×抗c-erbB-2单克隆抗体将CD4+辅助/杀伤T细胞靶向肿瘤会导致肿瘤裂解并引发IL-2产生。还证明用葡萄球菌肠毒素A(SEA)或IL-12培养人CD4+ T细胞会选择性诱导Th1型CD4+辅助/杀伤T细胞。IL-12还显示出对CD8+CTL功能的新作用。用IL-12培养CD8+ T细胞会导致IFN-γ产生和细胞毒性增强。此外,用IL-12培养肿瘤浸润淋巴细胞会显著增强CD8+CTL对自体肿瘤细胞的作用。这些发现表明IL-12将成为肿瘤免疫疗法中一种有用的细胞因子。在本文中,我们将讨论CD4+ T细胞在荷瘤宿主抗肿瘤免疫诱导中的关键作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验